Developing a first-in-class anti-inflammatory & anti-fibrotic monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
Developing a first-in-class anti-inflammatory & anti-fibrotic monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis.